Clinical and Molecular Findings of Infections Caused by Extended-Spectrum β-Lactamase-Producing in Patients with Solid Tumors: A Single-Center Study.

Infectious complications caused by multidrug-resistant bacteria are a serious clinical and therapeutic problem. Our study aimed to analyze the genetic characteristics of extended-spectrum β-lactamase-producing (ESBL-E) that cause multidrug-resistant infections in patients with solid tumors. Identification of ESBL-encoding genes was performed by polymerase chain reaction (PCR) and sequencing. The clonal relationship of the isolates was evaluated by pulsed-field gel electrophoresis. Multilocus sequence typing (MLST) was carried out for selected and isolates. All strains were classified into phylogenetic groups using the PCR-based approach. There were 735 patients with clinical symptoms of infections tested, of which 44 (6.0%) were positive for ESBL-E on genotypic testing. The most frequent organism was ( = 24, 54.5%), followed by ( = 13, 29.5%), ( = 3, 6.8%), cplx ( = 2, 4.5%), and ( = 2, 4.5%). Overall, 31 (70.5%) of the ESBL-E isolates carried only -like genes, and the genes were found to be ( = 30, 68.2%) or ( = 1, 2.3%). Eleven strains (25%) had -like genes, mostly ( = 10, 22.7%) and unique ( = 1, 2.3%). One isolate possessed both and genes, and another one produced TEM-12 ESBL. MLST analysis revealed sequence type (ST) 131 and ST361, and ST16, ST307, and ST437. Among isolates, the B2 phylogenetic group was predominant. Most of the strains showed resistance to third-generation cephalosporins and fluoroquinolones, and susceptibility to aminoglycosides and carbapenems. Patients with solid cancer and ESBL-E infections require special management since they are a population with a high threat of antibiotic-resistant infections. Carbapenems and aminoglycosides remain active antibiotics against these infections.